A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 in Healthy Adult Subjects
Latest Information Update: 06 Apr 2022
At a glance
- Drugs HLX 71 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Hengenix Biotech
- 20 Mar 2022 Status changed from recruiting to completed.
- 15 Oct 2020 New trial record